STAT+: House leaders to investigate FDA approval and price of Biogen’s Alzheimer’s drug
WASHINGTON — The top House Democrats on two powerful committees on Friday announced an investigation into the approval and pricing of Biogen’s controversial Alzheimer’s drug Aduhelm.
Both Biogen and the Food and Drug Administration will be under the microscope, House Committee on Oversight and Reform Chair Carolyn Maloney (D-N.Y.) and Energy & Commerce Chair Frank Pallone (D-N.J.) said.
